FARMINGDALE, N.Y., May 13 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has announced their attendance at the 22nd Annual Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS), which was held in Dallas, TX, April 26-29, 2009, and is widely regarded as the premier educational wound care-focused program in the United States. Also, the SAWC/WHS symposium is the official meeting of the Association for the Advancement of Wound Care (AAWC), a pre-eminent multi-disciplinary organization for wound care. Misonix exhibited and demonstrated its SonicOne(R) Ultrasonic Wound Cleansing and Debridement System to many of the approximately 2,300 clinicians in attendance.
As part of the therapeutic educational program, Oscar Alvarez, Ph.D., FAPWCA, Director of the Center for Curative and Palliative Wound Care at Calvary Hospital, Bronx, NY, and an Associate Professor of Medicine at
From humble beginnings in 1988, when a small group of nurses and physicians interested in this emerging discipline created a mission and vision to provide an interdisciplinary forum on wound care, the SAWC/WHS has grown, becoming the largest annual gathering of wound care clinicians in the United States. The SAWC/WHS partnership reflects the need for clinicians to better understand the research and science behind wound management in pursuit of optimal patient outcomes.
The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.
"Misonix is pleased to demonstrate its commitment to the large and rapidly growing wound care market by supporting important educational programs like SAWC/WHS and ASWC," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "The wound care product platform, we believe, can make an important contribution to improving patient outcomes and we are gratified when data is presented by clinical experts that support our investment in wound care Research and Development."
Misonix, Inc. (NASDAQ: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
|SOURCE Misonix, Inc.|
Copyright©2009 PR Newswire.
All rights reserved